SCHEDULE: JPMorgan Chase & Co. Discloses REGENXBIO Stake

JPMorgan Chase & Co. has filed a Schedule 13G, reporting beneficial ownership of 4.4% of REGENXBIO Inc.'s common stock as of May 29, 2026.

Summary

• JPMorgan Chase & Co. has filed an amendment to its Schedule 13G, indicating its beneficial ownership of REGENXBIO Inc. common stock.
• The filing reports that JPMorgan Chase & Co. beneficially owns 2,279,362 shares, representing 4.4% of the class of securities.
• This ownership level is considered 5% or less of a class, as per Item 5 of the filing.
• The filing is an amendment (Amendment No. 7) to a previous filing.
• The date of the event requiring this filing is May 29, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by an institutional investor and does not provide new operational or financial information about REGENXBIO Inc.

Positives

• JPMorgan Chase & Co. maintains a significant, though not controlling, stake in REGENXBIO Inc.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, suggesting standard investment activity.

Negatives

• The filing does not contain specific financial performance data for REGENXBIO Inc., focusing solely on ownership disclosure.

Risks

• As a holder of 4.4% of the shares, JPMorgan Chase & Co.'s investment is subject to the market and operational risks faced by REGENXBIO Inc.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from REGENXBIO Inc. It is a disclosure of ownership by JPMorgan Chase & Co.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors like JPMorgan Chase & Co. when their beneficial ownership of a public company's stock crosses certain thresholds. This filing indicates a passive investment approach rather than an attempt to gain control of REGENXBIO Inc.

Stakeholder Impact

• Shareholders of REGENXBIO Inc. are informed of a significant institutional investor's holdings, which can influence market perception and trading activity.

Next Steps

• JPMorgan Chase & Co. will continue to report any material changes in its beneficial ownership of REGENXBIO Inc. common stock as required by SEC regulations.

Key Dates

Keywords

REGENXBIO Inc., JPMorgan Chase & Co., Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Holding